288 related articles for article (PubMed ID: 19686694)
1. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
5. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.
Godefroy E; Scotto L; Souleimanian NE; Ritter G; Old LJ; Jotereau F; Valmori D; Ayyoub M
Clin Immunol; 2006 Oct; 121(1):54-62. PubMed ID: 16814609
[TBL] [Abstract][Full Text] [Related]
6. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
7. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
8. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
9. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
[TBL] [Abstract][Full Text] [Related]
10. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
[TBL] [Abstract][Full Text] [Related]
11. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
12. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
13. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
14. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
15. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
[TBL] [Abstract][Full Text] [Related]
16. Melanoma antigens recognised by CD8+ and CD4+ T cells.
Storkus WJ; Zarour HM
Forum (Genova); 2000; 10(3):256-70. PubMed ID: 11007933
[TBL] [Abstract][Full Text] [Related]
17. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity.
Tiwari R; Geliebter J; Lucchese A; Mittelman A; Kanduc D
Peptides; 2004 Nov; 25(11):1865-71. PubMed ID: 15501517
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
19. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
20. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine.
Monzavi-Karbassi B; Pashov A; Jousheghany F; Artaud C; Kieber-Emmons T
Int J Mol Med; 2006 Jun; 17(6):1045-52. PubMed ID: 16685414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
